D/C/F/TAF FDC Evaluated as a Fixed Dose Combination Regimen in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gainmidwayadmin2020-05-15T15:27:28+00:00
D/C/F/TAF FDC Evaluated as a Fixed Dose Combination Regimen in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain
TMC114FD2HTX4004 · Trial ·
Major Inclusion/Exclusion Criteria:
- Currently on Biktarvy, Genvoya, Tivicay/Descovy, or Isentress/Descovy for at least 6 months
- BMI >18
- >10% increase in body weight within a 12 month period since starting medication
- HIV RNA <50